FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MEI Pharma's Free Cash Flow for the
three
months ended in Dec. 2023 was $-11.06 Mil. MEI Pharma's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Therefore, MEI Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.
The historical rank and industry rank for MEI Pharma's FCF Margin % or its related term are showing as below:
MEIP'
s FCF Margin % Range Over the Past 10 Years
Min: -1296.86 Med: -107.59 Max: 120.2
Current: -72.92
During the past 13 years, the highest FCF Margin % of MEI Pharma was 120.20%. The lowest was -1296.86%. And the median was -107.59%.
MEIP's FCF Margin % is ranked better than 57.35% of 1034
companies
in the Biotechnology industry
Industry Median: -148.935
vs MEIP: -72.92
MEI Pharma FCF Margin % Historical Data
The historical data trend for MEI Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's FCF Margin %
For the Biotechnology subindustry, MEI Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MEI Pharma's FCF Margin % falls into.
MEI Pharma FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
MEI Pharma's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma FCF Margin % Related Terms
Thank you for viewing the detailed overview of MEI Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 